Live Geos: https://partners.subjectwell.com/publishers/geos_report/599d6ef7-3a3a-4bc0-a15f-2c3d6f823312 Ages: 15-17 Gender: All *All approved copy and creative can be found in the creative folder. If you choose to write your own copy or do your own creative, send to affiliates@subjectwell.com prior to launch or you risk being kicked out of the program Study Description: The purpose of this clinical study is to see whether an investigational drug can improve social communication in children and adolescents with autism spectrum disorder. Participants may qualify if they have been diagnosed or suspected of having autism spectrum disorder. Participants and a Study Care Partner may be asked to attend an initial screening visit to determine if they’re eligible to enroll in the study. If enrolled, participant will be randomly selected to receive either the study drug or a placebo to be taken by mouth once daily for 3 months. Total participation will last approximately 9 months and both participant and Study Care Partner will be required to attend 10 doctor’s visits throughout the study. Participants and Study Care Partner may be compensated for time. The doctor’s office conducting the study will be able to provide you with more information about the study requirements. Qualifications: - Cannot have had a seizure in past six months - Patient cannot experience migraines - Is participant taking any of the following medications?: Antidepressants, such as SSRIs, SNRIs, or MAOIs, Risperdal (risperidone), Abilify (aripriprazole), Tagamet (cimetidine)